Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
795
datasets available to search
ShareScore release 0.9.0
Dataset results
795 results for “Drug Safety”
The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months
ClinicalTrials.gov study NCT00224133. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Safety and Efficacy Comparator Trial of a New Drug Against Genital Herpes
ClinicalTrials.gov study NCT01658826. IPD Sharing: Not stated. Countries: 1. Publications: 1.
To Evaluate the Safety, Tolerability, and Efficacy of TMC207 as Part of an Individualized Multi-drug Resistant Tuberculosis (MDR-TB) Treatment Regimen in Participants With Sputum Smear-positive Pulmon
ClinicalTrials.gov study NCT00910871. IPD Sharing: Not stated. Countries: 12. Publications: 2.
An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD
ClinicalTrials.gov study NCT01985126. IPD Sharing: Not stated. Countries: 3. Publications: 6.
A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Low-Dose ICS Therapy.
ClinicalTrials.gov study NCT00603278. IPD Sharing: YES. Countries: 13. Publications: 3.
Data from: A curated and standardized adverse drug event resource to accelerate drug safety research
Identification of adverse drug reactions (ADRs) during the post-marketing phase is one of the most important goals of drug safety surveillance. Spontaneous reporting systems (SRS) data, which are the mainstay of traditional drug safety surveillance, are used for hypothesis generation and to validate the newer approaches. The publicly available US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) data requires substantial curation before they can be used appropriately, and applying different strategies for data cleaning and normalization can have material impact on analysis results. We provide a curated and standardized version of FAERS removing duplicate case records, applying standardized vocabularies with drug names mapped to RxNorm concepts and outcomes mapped to SNOMED-CT concepts, and pre-computed summary statistics about drug-outcome relationships for general consumption. This publicly available resource, along with the source code, will accelerate drug safety research by reducing the amount of time spent performing data management on the source FAERS reports, improving the quality of the underlying data, and enabling standardized analyses using common vocabularies.
Safe cardiac action potential test (www.scaptest.com) : a database describing the in silico cardiac safety profile of drugs and their propensity to induce early afterdepolarization - Part II : description of 50 additional drugs
<p><span>This file describes the<em> in silico</em> cardiac safety profile of 50 additional drugs (in addition to the 150 drugs already described in the zenodo file 7541554) in order to complete the “scaptest” database.<span> </span>The aim of this database is to describe the <em>in silico</em> cardiac safety profile of drugss and their propensity to induce early afterdepolarization.<span> </span>This is based on the study of the effects of drugs on the non-failing human ventricular myocyte action potential (endo-, mid- and epicardial subtypes) reconstructed by computational simulation (O’Hara-Rudy dynamic algorithm) in order to identify cardiac action potential abnormalities such as high variations and/or occurrence of resting membrane potential, action potential amplitude, maximal rate of action potential rise, action potential duration, triangulation, early afterdepolarization, transmural dispersion of repolarization, reverse use dependence, qNet or minimal rate of action potential decrease at early afterdepolarization take-off voltage. These various parameters are useful in order to assume a more accurate predictability of pro-arrhythmic liabilities of new drug candidate in the cardiac safety pharmacology screening process, which is the aim of the comprehensive in vitro pro-arrhythmia assay (CiPA) initiative. The <em>in silico</em> cardiac safety profile of each drug is illustrated by a separate page describing the effects induced by each compound on these various parameters. The results are summarized regarding the expected pro-arrhythmia profile of the various compounds as described by the CredibleMeds classification evaluating their propensity to induce torsade de pointes.</span></p>
Safe cardiac action potential test (www.scaptest.com): a database describing the in silico cardiac safety profile of drugs and their propensity to induce early afterdepolarization
<p>The aim of the present database is to describe the <em>in silico</em> cardiac safety profile of drugs and their propensity to induce early afterdepolarization. This is based on the study of the effects of drugs on the non-failing human ventricular myocyte action potential (endo-, mid- and epicardial subtypes) reconstructed by computational simulation (O’Hara-Rudy dynamic algorithm) in order to identify cardiac action potential abnormalities such as high variations and/or occurrence of resting membrane potential, action potential amplitude, maximal rate of action potential rise, action potential duration, triangulation, early afterdepolarization, transmural dispersion of repolarization, reverse use dependence, qNet or minimal rate of action potential decrease at early afterdepolarization take-off voltage. These various parameters are useful in order to assume a more accurate predictability of pro-arrhythmic liabilities of new drug candidate in the cardiac safety pharmacology screening process, which is the aim of the comprehensive in vitro pro-arrhythmia assay (CiPA) initiative. The <em>in silico</em> cardiac safety profile of each drug (150 drugs described in this first version) is illustrated by a separate page describing the effects induced by each compound on these various parameters. The results are summarized regarding the expected pro-arrhythmia profile of the various compounds as described by the CredibleMeds classification evaluating their propensity to induce torsade de pointes.</p>
A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Pr
ClinicalTrials.gov study NCT04147819. IPD Sharing: NO. Countries: 2. Publications: 1.
A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Rec
ClinicalTrials.gov study NCT02770378. IPD Sharing: NO. Countries: 1. Publications: 2.
Safety and Efficacy of Drug Combinations Against Triple Infections
ClinicalTrials.gov study NCT01050517. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study Investigating the Safety, Absorption and Elimination of GLPG3312, a New Drug in the Treatment of Inflammatory Diseases
ClinicalTrials.gov study NCT03800472. IPD Sharing: Not stated. Countries: 1. Publications: 1.
An Open Study of the Safety, Tolerability and Immunogenicity of the Drug "Gam-COVID-Vac" Vaccine Against COVID-19
ClinicalTrials.gov study NCT04436471. IPD Sharing: NO. Countries: 1. Publications: 1.
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
ClinicalTrials.gov study NCT04278404. IPD Sharing: NO. Countries: 2. Publications: 11.
Comparison of the Pharmacokinetics and Safety of Two SAR231893 (REGN668) Drug Products in Healthy Subjects
ClinicalTrials.gov study NCT01537640. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Efficacy and Safety of an Oral Growth Hormone Drug in the Treatment of Fibromyalgia
ClinicalTrials.gov study NCT00116129. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Safety and Efficacy of the ZoMaxx™ Drug-Eluting Stent System in Coronary Arteries
ClinicalTrials.gov study NCT00148356. IPD Sharing: Not stated. Countries: 10. Publications: 1.
Safety and Effectiveness of Four Anti-HIV Drug Combinations in HIV-Infected Children and Teens
ClinicalTrials.gov study NCT00001091. IPD Sharing: Not stated. Countries: 2. Publications: 8.
The Benefit and Safety of Older Generation Anti-Epileptic Drugs (AEDs) in Drug-Resistant Epilepsy Children
ClinicalTrials.gov study NCT05697614. IPD Sharing: NO. Countries: 1. Publications: 1.
Efficacy and Safety of Vildagliptin Compared to Acarbose in Drug Naive Patients With Type 2 Diabetes
ClinicalTrials.gov study NCT00110240. IPD Sharing: Not stated. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.